FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 233 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... June 29, 2021 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion February 19, 2025 The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... March 31, 2021 Load more HOT NEWS How People With Advanced Cancer Can Find Meaning Toward the End... Making a startup out of a scientist E-cigarettes: what we know and what we don’t Mom Fights Second Round Of Breast Cancer — Weeks Later, Her...
